COVALENT-112 Phase II data boost momentum for ico, Biomea Fusion pushes first-in-class strategy

Traders Union
All News
Business & Wealth
Biomea Fusion advances Phase II ico

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

25.06.2026

COVALENT-112 Phase II data boost momentum for ico, Biomea Fusion pushes first-in-class strategy — Biomea Fusion advances Phase II ico

Biomea Fusion announced new progress in its Phase II COVALENT-112 trial for type 1 diabetes, marking a significant development in the search for novel treatments.

Dr. Jason Gaglia of Joslin Diabetes Center, commenting on the findings, emphasized that ico targets a previously underexplored disease pathway. The company is moving forward with ico as a potential first-in-class approach, underscoring its commitment to innovation in diabetes care. The results could open new therapeutic avenues for patients with type 1 diabetes.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier this year, Biomea Fusion met with global industry leaders at the BIO International Convention to explore new collaboration opportunities. The company also identified key innovation and research themes in diabetes care at the ADA2026 event. These activities highlight Biomea Fusion's ongoing engagement with sector trends and partnerships.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Asia's largest IPO: How CXMT became China's most valuable company

By Mikhail Vnuchkov
2 hours ago

Asia's largest IPO: How CXMT became China's most valuable company

Editors' Picks

Global fintech in 2026: Three trends that matter

By Pavlo Kot
Yesterday

Global fintech in 2026: Three trends that matter

Editors' Picks

From Jesus Christ to aliens: Polymarket's most absurd prediction markets

By Pavlo Kot
25.07.2026

From Jesus Christ to aliens: Polymarket's most absurd prediction markets

Editors' Picks

All Editors' Top Picks

Latest Biomea Fusion News

Biomea Fusion launches Phase II trial for icovamenib in type 1 diabetes

By Olga Shendetskaya
24.07.2026

Biomea Fusion launches Phase II trial for icovamenib in type 1 diabetes

Companies

Biomea Fusion outlines key stages involved in clinical trials for new medicines

By Andreas Kristo
22.07.2026

Biomea Fusion outlines key stages involved in clinical trials for new medicines

Companies

Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting

By Jose Antonio Gastelum
10.07.2026

Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting

Companies

All Biomea Fusion News

Mikhail Vnuchkov
2 hours ago

Asia's largest IPO: How CXMT became China's most valuable company

Pavlo Kot
Yesterday

Global fintech in 2026: Three trends that matter

Pavlo Kot
25.07.2026

From Jesus Christ to aliens: Polymarket's most absurd prediction markets

Andrey Mastykin
25.07.2026

Hunting crypto owners: Why criminals have gone offline

Eugene Komchuk
24.07.2026

BitMEX is shutting down: Why Trump could not save the exchange

Hanna Syniavska
7 min ago

Sjuul Follings: Profitable trade on PUMP after buying the dip ahead of price surge

Eugene Komchuk
12 min ago

Audience receives message on Tesla, George Noble notes

Parshwa Turakhiya
31 min ago

China crude imports set to recover from decade low, Tracy Shuchart notes

Jose Antonio Gastelum
36 min ago

Adam Back: Rejecting forced changes is key to Bitcoin's immutability

Artem Shendetskii
37 min ago

Current tech stock dip less drastic than past downturns, Brian Sozzi notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Olga Shendetskaya
48 min ago

CME Group launches futures on 55 major U.S. stocks

CME Group launches futures on 55 major U.S. stocks

Ivan Andriyenko
2 hours ago

Nvidia considers $250 billion support for OpenAI project

Nvidia considers $250 billion support for OpenAI project

Hanna Syniavska
3 hours ago

Brent falls below $90 as Middle East tensions ease

Brent falls below $90 as Middle East tensions ease

Eugene Komchuk
4 hours ago

Storj Labs files for bankruptcy

Storj Labs files for bankruptcy

Pavlo Kot
Yesterday

Global fintech in 2026: Three trends that matter

Global fintech in 2026: Three trends that matter

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

Mixed quarterly results keep BT Group shares in consolidation

Mykhailo Ihnatenko
Now

Rolls-Royce shares near record high ahead of half-year results

Mykhailo Ihnatenko
Now

Solana price follows crypto rebound but volume remains weak

Mykhailo Ihnatenko
Now

Ethereum price eyes $2,000 as U.S.-Iran tensions ease

Anton Kharitonov
Now

Microsoft steadies after selloff as AI fundamentals remain intact

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.